Co-Diagnostics, Inc.
Company Information
Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation UT
Business Address 2401 S FOOTHILL DRIVE, SALT LAKE CITY, UT, 84109
Mailing Address 2401 S FOOTHILL DRIVE, SALT LAKE CITY, UT, 84109
Phone 8014381036
Fiscal Year End 1231
EIN 462609396
Financial Overview
FY2025
$9.69M
Total Liabilities
$11.88M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 11, 2026 | View on SEC |
| 8-K Current report of material events | January 13, 2026 | View on SEC |
| 8-K Current report of material events | December 30, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 19, 2025 | View on SEC |
| 8-K Current report of material events | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | November 24, 2025 | View on SEC |
| 4 Insider stock transaction report | November 24, 2025 | View on SEC |
Annual Reports
10-K March 31, 2026
- Developing the Co-Dx PCR platform for portable, smartphone-connected home testing.
- Proprietary 'Co-Primers' technology offers potential for lower production costs and higher accuracy.
Material Events
8-K Other March 10, 2026
High Impact
- Co-Diagnostics successfully regained compliance with Nasdaq's minimum bid price requirement, averting immediate delisting.
- The company reported an estimated $11.9 million in cash and cash equivalents as of December 31, 2025.
8-K Strategy Change December 30, 2025
High Impact
- Co-Diagnostics, Inc. announced a 1-for-30 reverse stock split.
- The split will become effective at the end of January 1, 2026, with shares trading on a split-adjusted basis starting January 2, 2026.
8-K Strategy Change December 5, 2025
High Impact
- Co-Diagnostics' shareholders approved a reverse stock split plan.
- The Board of Directors has up to 12 months to decide the exact ratio, ranging from 1-for-2 to 1-for-30.
Related Companies
Companies in the same industry (SIC: 3841)
OSR Holdings, Inc.
OSRH Surgical & Medical Instruments & Apparatus
NEXGEL, INC.
NXGL Surgical & Medical Instruments & Apparatus
Catheter Precision, Inc.
VTAK Surgical & Medical Instruments & Apparatus
VYCOR MEDICAL INC
VYCO Surgical & Medical Instruments & Apparatus
Sharps Technology Inc.
STSS Surgical & Medical Instruments & Apparatus
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.